Drug Trial Radar · NCT03180307
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jan 26, 2018
Primary completion
Apr 16, 2020
Study completion Oct 16, 2020
Sponsor
- Lead sponsor
- On Target Laboratories, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- SynteractHCR
- First posted
- Jun 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.
Conditions
- Ovarian Cancer
Interventions
OTL38Drug
0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
near infrared camera imaging systemDevice
Infrared imaging used to excite OTL38 for fluorescence
laparotomyProcedure
primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Patient LevelTime frame: 30 days
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
The Mayo Clinic - Phoenix
Phoenix, Arizona
University of Arizona
Tucson, Arizona
City of Hope Medical Center
Duarte, California
University of CA at Irvine Chao Cancer Center
Orange, California
Moffitt Cancer Center
Tampa, Florida
Karmanos Cancer Institutes
Detroit, Michigan
Mayo Clinic-Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Kettering Medical Center
Kettering, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Leiden University Medical Center
Leiden, South Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.